Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis
Background: Hypertension, a risk factor for cardiovascular events, is often associated with chronic kidney disease. This is called hypertensive nephropathy (HN), which negatively affects physical fitness and body mass, leading to economic burden. Traditional Chinese medicine injections (TCMIs) are c...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.740821/full |
_version_ | 1818834081942601728 |
---|---|
author | Zhe Chen Yingying Peng Yingying Peng Fengwen Yang Xiaoyu Qiang Yong Chen Yongjie Chen Lujia Cao Chunxiang Liu Junhua Zhang |
author_facet | Zhe Chen Yingying Peng Yingying Peng Fengwen Yang Xiaoyu Qiang Yong Chen Yongjie Chen Lujia Cao Chunxiang Liu Junhua Zhang |
author_sort | Zhe Chen |
collection | DOAJ |
description | Background: Hypertension, a risk factor for cardiovascular events, is often associated with chronic kidney disease. This is called hypertensive nephropathy (HN), which negatively affects physical fitness and body mass, leading to economic burden. Traditional Chinese medicine injections (TCMIs) are common traditional Chinese-patent medicine preparations in China. There was a lack of evidence to prove which TCMIs combine with ADs (TCMIs+ADs) may be a therapeutic option for HN. Thus, we systematically reviewed the efficacy and safety of various TCMIs + ADs in patients with HN.Methods: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for relevant Chinese- and English-language randomized controlled trials (RCTs) published from database inception until May 2021. Literature screening, data extraction, and quality assessment was performed by two reviewers independently but using the same criteria. We performed the effect modeling to analyze the data for all outcomes and ranked each intervention using the P-score. Furthermore, sensitivity analysis, meta-regression, and funnel plots were used to test the stability, heterogeneity, and publication bias, respectively.Results: We included 69 RCTs with 6373 patients and including six TCMIs + ADs. Network analysis indicated that the ginkgo leaf extract and dipyridamole combined with ADs (GLED + ADs) was the most efficacious in terms of 24-h urinary protein excretion [mean difference (MD) = −0.70, 95% confidence interval (CI): −0.82 to −0.58; P-score = 1] and systolic blood pressure (MD = −12.95, 95% CI: −21.03 to −4.88; P-score = 0.88), whereas the salvianolate combined with ADs (SA + ADs) showed the highest effectiveness for diastolic blood pressure (MD = −6.88, 95% CI: −10.55 to −3.21; P-score = 0.9). Based on the combined P-score of network meta-analysis results (88% and 85.26%) and sensitivity analysis results (72% and 71.54%), the biplots showed that the GLED + ADs was the most efficacious intervention in all TCMIs + ADs for primary outcomes, followed by the SA + ADs and sodium tanshinone IIA sulfonate combined with ADs (STS + ADs). There was no significant difference in terms of safety between TCMIs + ADs and ADs alone.Conclusion: Of all the TCMIs + ADs, GLED + ADs, SA + ADs, and STS + ADs may demonstrate a higher efficacy than ADs alone for HN. Weighing with the potential benefits and limitations in methodology, potential heterogeneity and outcomes, we should use various TCMIs with caution in clinical practice. Nevertheless, additional high-quality RCTs are warranted and future research should focus on the clinical value of core outcomes to confirm the effectiveness and safety of TCMIs for HN.Systematic Review Registration: clinicaltrials.gov, identifier CRD42020205358 |
first_indexed | 2024-12-19T02:29:09Z |
format | Article |
id | doaj.art-8a59f42fc1224db9a23a2d8bc2ca3116 |
institution | Directory Open Access Journal |
issn | 1663-9812 |
language | English |
last_indexed | 2024-12-19T02:29:09Z |
publishDate | 2021-10-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Pharmacology |
spelling | doaj.art-8a59f42fc1224db9a23a2d8bc2ca31162022-12-21T20:39:45ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-10-011210.3389/fphar.2021.740821740821Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-AnalysisZhe Chen0Yingying Peng1Yingying Peng2Fengwen Yang3Xiaoyu Qiang4Yong Chen5Yongjie Chen6Lujia Cao7Chunxiang Liu8Junhua Zhang9Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaEvidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaGraduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaDepartment of Epidemiology and Statistic, School of Public Health, Tianjin Medical University, Tianjin, ChinaEvidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaEvidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaBackground: Hypertension, a risk factor for cardiovascular events, is often associated with chronic kidney disease. This is called hypertensive nephropathy (HN), which negatively affects physical fitness and body mass, leading to economic burden. Traditional Chinese medicine injections (TCMIs) are common traditional Chinese-patent medicine preparations in China. There was a lack of evidence to prove which TCMIs combine with ADs (TCMIs+ADs) may be a therapeutic option for HN. Thus, we systematically reviewed the efficacy and safety of various TCMIs + ADs in patients with HN.Methods: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for relevant Chinese- and English-language randomized controlled trials (RCTs) published from database inception until May 2021. Literature screening, data extraction, and quality assessment was performed by two reviewers independently but using the same criteria. We performed the effect modeling to analyze the data for all outcomes and ranked each intervention using the P-score. Furthermore, sensitivity analysis, meta-regression, and funnel plots were used to test the stability, heterogeneity, and publication bias, respectively.Results: We included 69 RCTs with 6373 patients and including six TCMIs + ADs. Network analysis indicated that the ginkgo leaf extract and dipyridamole combined with ADs (GLED + ADs) was the most efficacious in terms of 24-h urinary protein excretion [mean difference (MD) = −0.70, 95% confidence interval (CI): −0.82 to −0.58; P-score = 1] and systolic blood pressure (MD = −12.95, 95% CI: −21.03 to −4.88; P-score = 0.88), whereas the salvianolate combined with ADs (SA + ADs) showed the highest effectiveness for diastolic blood pressure (MD = −6.88, 95% CI: −10.55 to −3.21; P-score = 0.9). Based on the combined P-score of network meta-analysis results (88% and 85.26%) and sensitivity analysis results (72% and 71.54%), the biplots showed that the GLED + ADs was the most efficacious intervention in all TCMIs + ADs for primary outcomes, followed by the SA + ADs and sodium tanshinone IIA sulfonate combined with ADs (STS + ADs). There was no significant difference in terms of safety between TCMIs + ADs and ADs alone.Conclusion: Of all the TCMIs + ADs, GLED + ADs, SA + ADs, and STS + ADs may demonstrate a higher efficacy than ADs alone for HN. Weighing with the potential benefits and limitations in methodology, potential heterogeneity and outcomes, we should use various TCMIs with caution in clinical practice. Nevertheless, additional high-quality RCTs are warranted and future research should focus on the clinical value of core outcomes to confirm the effectiveness and safety of TCMIs for HN.Systematic Review Registration: clinicaltrials.gov, identifier CRD42020205358https://www.frontiersin.org/articles/10.3389/fphar.2021.740821/fulltraditional Chinese medicine injectionsantihypertensive drugshypertensive nephropathynetwork meta-analysisrandomized controlled trial |
spellingShingle | Zhe Chen Yingying Peng Yingying Peng Fengwen Yang Xiaoyu Qiang Yong Chen Yongjie Chen Lujia Cao Chunxiang Liu Junhua Zhang Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis Frontiers in Pharmacology traditional Chinese medicine injections antihypertensive drugs hypertensive nephropathy network meta-analysis randomized controlled trial |
title | Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis |
title_full | Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis |
title_fullStr | Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis |
title_full_unstemmed | Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis |
title_short | Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis |
title_sort | traditional chinese medicine injections combined with antihypertensive drugs for hypertensive nephropathy a network meta analysis |
topic | traditional Chinese medicine injections antihypertensive drugs hypertensive nephropathy network meta-analysis randomized controlled trial |
url | https://www.frontiersin.org/articles/10.3389/fphar.2021.740821/full |
work_keys_str_mv | AT zhechen traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT yingyingpeng traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT yingyingpeng traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT fengwenyang traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT xiaoyuqiang traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT yongchen traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT yongjiechen traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT lujiacao traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT chunxiangliu traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis AT junhuazhang traditionalchinesemedicineinjectionscombinedwithantihypertensivedrugsforhypertensivenephropathyanetworkmetaanalysis |